An Zepbound injection enclosure, Eli Lilly’s weight loss medication, is displayed in New York on December 11, 2023.
Brendan McDermid | Reuters
Eli Lilly Pursuing four television companies selling versions made up of the weight loss drug of the Zepbound pharmaceutical giant and its treatment of diabetes Mounjaro, the company’s last attempt to repress the booming of copy medication.
In the prosecution deposited Wednesday, Lilly accuses the sites – Mochi Health, Fella Health, Willow Health and Henry Medds – of deceiving consumers on “unprepared drugs” and keep them away from Lilly’s medicines.
Lilly alleges that companies claim to offer personalized options when they are in fact slightly different versions of Lilly drugs in order to bypass the rules of the FDA. Lilly also claims that some sites sell medicines that have not been studied, such as tablets and oral drops.
Mochi, Fella, Willow and Henry Meds did not immediately respond to CNBC comments.
Lilly Mounjaro’s diabetes against diabetes broken down at the end of 2022, allowing pharmacies and outsourcing installations to produce treatment, a practice called composition. Novo Nordisk Wegovy’s weight loss drug was also shortened, opening the market for the composition of GLP-1.
This company exploded online, where people looked for treatment versions if they could not find brand names Or could not make them covered by insurance. The mass composition of the shooting, the active ingredient of Mounjaro and Zepbound, was to stop last month after the Food and Drug Administration declared the shortage of the drugs.
Some pharmacies have continued to do so anyway, producing versions that differ slightly from the brand, which could possibly keep them out of the FDA reticle. Earlier this month, Lilly continued two pharmacies, alleging that they have falsely marketed their products as personalized versions of drugs that have been clinically tested and are manufactured using strict safety standards.
One of the Lilly Télésanty platforms is continuing now, Mochi Health, plans to continue selling versions composed of shooting, betting that the offer of personalized treatments would prevent legal troubles, the CEO of Mochi Myra Ahmad told CNBC in March.
When asked if she feared Lilly’s legal action, Ahmad said that she was not worried about her prescribers because “they established patient-doctor relationships” and “the beauty of medicine is really that they get complete autonomy to decide what is the best way to manage their patients”.
Lilly in her deposit on Wednesday said that Hmad was not an approved doctor and that Mochi and his “license without license exerts an excessive influence and control, among others, the decisions of prescription of doctors” and are therefore engaged in the “practice of illegal medicine companies”.
Lilly makes a similar allegation against Fella Health, accusing the company of “radical corporate decisions that dictate patient care, as when Fella has changed mass patients from a shooting of shooting to another with additives”.
In the four cases, Lilly seeks to prevent sites from marketing or selling shooting. But that could take months, or even more, so that business can do in court.